UOB Kay Hian Maintains ALI HEALTH (00241) Target Price at HK$7.8 and "Buy" Rating, as H1 FY2026 Results Beat Expectations

Stock News11-28

UOB Kay Hian has reiterated its target price of HK$7.8 and a "Buy" rating for ALI HEALTH (00241), following the company's better-than-expected financial results for the first half of fiscal year 2026. ALI HEALTH reported a 17% year-on-year increase in revenue and a 38.7% rise in adjusted net profit, surpassing both the bank's and market consensus estimates. The company reaffirmed its fiscal year 2026 (ending September 30) targets of 10-15% revenue growth and 20-30% adjusted net profit growth.

The bank projects that ALI HEALTH will achieve a compound annual growth rate (CAGR) of 13% in revenue and 24% in adjusted net profit from fiscal 2026 to 2028. This growth is expected to be driven by sustained momentum in innovative drugs/healthcare products, deeper synergies with Alibaba's ecosystem, and expanding AI applications.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1102094676?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-28 13:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1102094676","market":"hk","top_or_hot":-1,"title":"UOB Kay Hian Maintains ALI HEALTH (00241) Target Price at HK$7.8 and \"Buy\" Rating, as H1 FY2026 Results Beat Expectations","media":"Stock News","content":"<p>UOB Kay Hian has reiterated its target price of HK$7.8 and a \"Buy\" rating for ALI HEALTH (00241), following the company's better-than-expected financial results for the first half of fiscal year 2026. ALI HEALTH reported a 17% year-on-year increase in revenue and a 38.7% rise in adjusted net profit, surpassing both the bank's and market consensus estimates. The company reaffirmed its fiscal year 2026 (ending September 30) targets of 10-15% revenue growth and 20-30% adjusted net profit growth.</p>\n<p>The bank projects that ALI HEALTH will achieve a compound annual growth rate (CAGR) of 13% in revenue and 24% in adjusted net profit from fiscal 2026 to 2028. This growth is expected to be driven by sustained momentum in innovative drugs/healthcare products, deeper synergies with Alibaba's ecosystem, and expanding AI applications.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UOB Kay Hian Maintains ALI HEALTH (00241) Target Price at HK$7.8 and \"Buy\" Rating, as H1 FY2026 Results Beat Expectations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUOB Kay Hian Maintains ALI HEALTH (00241) Target Price at HK$7.8 and \"Buy\" Rating, as H1 FY2026 Results Beat Expectations\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-28 13:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>UOB Kay Hian has reiterated its target price of HK$7.8 and a \"Buy\" rating for ALI HEALTH (00241), following the company's better-than-expected financial results for the first half of fiscal year 2026. ALI HEALTH reported a 17% year-on-year increase in revenue and a 38.7% rise in adjusted net profit, surpassing both the bank's and market consensus estimates. The company reaffirmed its fiscal year 2026 (ending September 30) targets of 10-15% revenue growth and 20-30% adjusted net profit growth.</p>\n<p>The bank projects that ALI HEALTH will achieve a compound annual growth rate (CAGR) of 13% in revenue and 24% in adjusted net profit from fiscal 2026 to 2028. This growth is expected to be driven by sustained momentum in innovative drugs/healthcare products, deeper synergies with Alibaba's ecosystem, and expanding AI applications.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1617","symbol_name":"AI医疗","start_time":0,"source_url":"","article_id":"1102094676","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1102094676","pubTimestamp":1764309018,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"UOB Kay Hian has reiterated its target price of HK$7.8 and a \"Buy\" rating for ALI HEALTH (00241), following the company's better-than-expected financial results for the first half of fiscal year...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1617":"AI医疗","BK1501":"阿里概念股","BK1584":"蚂蚁金服概念","BK1571":"互联网医疗","BK1589":"北水核心资产","BK1515":"抗疫概念","BK1610":"ETF&股票定投概念","BK1142":"互联网与直销零售","BK1502":"双十一","BK1591":"就地过年概念","00241":"阿里健康","BK1615":"港股-互联网","BK1189":"医疗保健技术","BK1247":"药品零售"},"translate_title":"大华继显维持阿里健康(00241)目标价7.8港元及“买入”评级，因2026财年H1业绩超预期","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00241":1},"content_text":"UOB Kay Hian has reiterated its target price of HK$7.8 and a \"Buy\" rating for ALI HEALTH (00241), following the company's better-than-expected financial results for the first half of fiscal year 2026. ALI HEALTH reported a 17% year-on-year increase in revenue and a 38.7% rise in adjusted net profit, surpassing both the bank's and market consensus estimates. The company reaffirmed its fiscal year 2026 (ending September 30) targets of 10-15% revenue growth and 20-30% adjusted net profit growth.\nThe bank projects that ALI HEALTH will achieve a compound annual growth rate (CAGR) of 13% in revenue and 24% in adjusted net profit from fiscal 2026 to 2028. This growth is expected to be driven by sustained momentum in innovative drugs/healthcare products, deeper synergies with Alibaba's ecosystem, and expanding AI applications.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1102094676","isCrawlerRequest":true}